BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 03, 2022 16:01 ET
|
BioAtla, Inc.
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolledBA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in...
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
October 27, 2022 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress
August 09, 2022 16:05 ET
|
BioAtla, Inc.
Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the study; anticipate full interim data set in...
BioAtla to Participate in the 2022 BTIG Biotechnology Conference
August 03, 2022 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022
August 02, 2022 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in 2022 Jefferies Global Healthcare Conference
June 01, 2022 16:05 ET
|
BioAtla, Inc.
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress
May 04, 2022 16:01 ET
|
BioAtla, Inc.
– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma – – Mecbotamab vedotin (BA3011) Phase 2 interim analysis in NSCLC anticipated in first...
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022
April 08, 2022 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...